FDA approves Steglatro for Type II diabetes

FDA approved Steglatro ertugliflozin from Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. The agency also approved the drug in two fixed-dose combinations -- Steglujan ertugliflozin/sitagliptin and Segluromet ertugliflozin/metformin -- for the indication.

In January, Merck plans to launch Steglatro at a wholesale acquisition cost (WAC) of $8.94 per day and Steglujan at a WAC of $17.45 per day. Segluromet's launch is planned for February at a WAC of $8.94 per day...